___

• 1. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune
• disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (8): 1037-56.
• 2. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-96.
• 3. Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellular immunity associated with chronic mucocutaneous moniliasis
• and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol 1968; 3 (2): 153-69.
• 4. Bach FH, Albertini RJ, Joo P, et al. Bone marrow transplantation in a patient with Wiskott-Aldrich syndrome. Lancet 1968; 2 (7583): 1364-66.
• 5. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric
• allogeneic transplantation: a consensus statement from the Children’s Oncology Group (COG) Transplant Discipline Committee
• and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006; 46 (4): 414-21.
• 6. Yesilipek MA, Hazar V, Küpesiz A, Kizilörs A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with betathalassemia. Bone Marrow Transplant 2001; 28 (11): 1037-40.
• 7. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric
• blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 2005; 35 (4): 361-67.
• 8. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest:
• ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46 (4): 422-33.
• 9. Rocha V, Gluckman E. Eurocord-Netcord registry and European Blood and Marrow Transplant group. Improving outcomes
• of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009; 147 (2): 262-74.
• 10. Brunstein CG, Weisdorf DJ. Future of cord blood for oncology uses. Bone Marrow Transplant 2009; (44): 699-707.
• 11. Kögler G, Critser P, Trapp T, Yoder M. Future of cord blood for non-oncology uses. Bone Marrow Transplant 2009; (44): 683-97.
• 12. Yeşilipek MA. Çocuklarda hematopoetik kök hücre nakli. Türk Ped Arş 2014; 49: 91-98.
• 13. Gratwohl A. Principals of conditioning. In: Apperly J, Carreras E, Gluckman E Grawthol A, Masszi T, (eds). Hematopoetic
• Stem Cell Transplantation, The EBMT Handbook. European School of Hematology, 2008: 128-44.
• 14. Kansoy S. Çocukluk çağı solid tümörlerinde HKH naklinin yeri. 9. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, 3-5 Mart 2016, Antalya, s: 32-34.
• 15.Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines
• from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21 (11): 1863-69.
• 16. Indications for HSCT in Children- UK Paediatric BMT Group 2015, UK Paediatric BMT Group HSCT Indications, 15 October 2015.
• 17. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (8): 1037-56.
• 18. Nucci M, Andrade F, Vigorito A, et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis 2003; 5: 167-73.
• 19. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility
• and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-80.
• 20. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-91.
• 21. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after haematopoietic cell transplantation: joint recommendations of the
• European Group for Blood and Marrow Transplantation, Centre for International, Blood and Marrow Transplant Research,
• and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006; 37: 249-61.
• 22. Cohen A, Békássy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41 (Suppl 2): S43-48.
• 23. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-58.
• 24. Dietz AC, Duncan CN, Alter BP, et al. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic
• Cell Transplantation (HCT): Defining the Unique Late Effects of Children Undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant 2016: S1083-8791 (16) 30396-2.
• Bu Makale Klinik Tıp Pediatri Dergisi’nin Cilt 8 Sayı 6 Kasım - Aralık 2016 saysından alınarak tıpkısının aynısı olarak yayınlamıştır.